img

Global Meningococcal Disease Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Meningococcal Disease Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
Meningococcal Disease Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Meningococcal Disease Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Infant and Child are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Meningococcal Disease Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Meningococcal Disease Vaccine key manufacturers include AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Sanofi and Merck & Co., Inc., etc. AstraZeneca, Johnson & Johnson, Mylan N.V are top 3 players and held % sales share in total in 2022.
Meningococcal Disease Vaccine can be divided into Polysaccharide, Conjugate and Combination,, etc. Polysaccharide is the mainstream product in the market, accounting for % sales share globally in 2022.
Meningococcal Disease Vaccine is widely used in various fields, such as Infant, Child and Aldult,, etc. Infant provides greatest supports to the Meningococcal Disease Vaccine industry development. In 2022, global % sales of Meningococcal Disease Vaccine went into Infant filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Meningococcal Disease Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


AstraZeneca
Johnson & Johnson
Mylan N.V
Teva Pharmaceutical Industries Ltd
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Baxter
BIO-MED
Bio-Manguinhos
Walvax Biotechnology Co., Ltd
Segment by Type
Polysaccharide
Conjugate
Combination

Segment by Application


Infant
Child
Aldult

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Meningococcal Disease Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Meningococcal Disease Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Meningococcal Disease Vaccine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Meningococcal Disease Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Meningococcal Disease Vaccine introduction, etc. Meningococcal Disease Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Meningococcal Disease Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Meningococcal Disease Vaccine Market Overview
1.1 Meningococcal Disease Vaccine Product Overview
1.2 Meningococcal Disease Vaccine Market Segment by Type
1.2.1 Polysaccharide
1.2.2 Conjugate
1.2.3 Combination
1.3 Global Meningococcal Disease Vaccine Market Size by Type
1.3.1 Global Meningococcal Disease Vaccine Market Size Overview by Type (2024-2034)
1.3.2 Global Meningococcal Disease Vaccine Historic Market Size Review by Type (2024-2024)
1.3.3 Global Meningococcal Disease Vaccine Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Meningococcal Disease Vaccine Sales Breakdown by Type (2024-2024)
1.4.2 Europe Meningococcal Disease Vaccine Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific Meningococcal Disease Vaccine Sales Breakdown by Type (2024-2024)
1.4.4 Latin America Meningococcal Disease Vaccine Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa Meningococcal Disease Vaccine Sales Breakdown by Type (2024-2024)
2 Global Meningococcal Disease Vaccine Market Competition by Company
2.1 Global Top Players by Meningococcal Disease Vaccine Sales (2024-2024)
2.2 Global Top Players by Meningococcal Disease Vaccine Revenue (2024-2024)
2.3 Global Top Players by Meningococcal Disease Vaccine Price (2024-2024)
2.4 Global Top Manufacturers Meningococcal Disease Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Meningococcal Disease Vaccine Market Competitive Situation and Trends
2.5.1 Meningococcal Disease Vaccine Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Meningococcal Disease Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Meningococcal Disease Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Meningococcal Disease Vaccine Market
2.8 Key Manufacturers Meningococcal Disease Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Meningococcal Disease Vaccine Status and Outlook by Region
3.1 Global Meningococcal Disease Vaccine Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global Meningococcal Disease Vaccine Historic Market Size by Region
3.2.1 Global Meningococcal Disease Vaccine Sales in Volume by Region (2024-2024)
3.2.2 Global Meningococcal Disease Vaccine Sales in Value by Region (2024-2024)
3.2.3 Global Meningococcal Disease Vaccine Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global Meningococcal Disease Vaccine Forecasted Market Size by Region
3.3.1 Global Meningococcal Disease Vaccine Sales in Volume by Region (2024-2034)
3.3.2 Global Meningococcal Disease Vaccine Sales in Value by Region (2024-2034)
3.3.3 Global Meningococcal Disease Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Meningococcal Disease Vaccine by Application
4.1 Meningococcal Disease Vaccine Market Segment by Application
4.1.1 Infant
4.1.2 Child
4.1.3 Aldult
4.2 Global Meningococcal Disease Vaccine Market Size by Application
4.2.1 Global Meningococcal Disease Vaccine Market Size Overview by Application (2024-2034)
4.2.2 Global Meningococcal Disease Vaccine Historic Market Size Review by Application (2024-2024)
4.2.3 Global Meningococcal Disease Vaccine Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Meningococcal Disease Vaccine Sales Breakdown by Application (2024-2024)
4.3.2 Europe Meningococcal Disease Vaccine Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific Meningococcal Disease Vaccine Sales Breakdown by Application (2024-2024)
4.3.4 Latin America Meningococcal Disease Vaccine Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa Meningococcal Disease Vaccine Sales Breakdown by Application (2024-2024)
5 North America Meningococcal Disease Vaccine by Country
5.1 North America Meningococcal Disease Vaccine Historic Market Size by Country
5.1.1 North America Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America Meningococcal Disease Vaccine Sales in Volume by Country (2024-2024)
5.1.3 North America Meningococcal Disease Vaccine Sales in Value by Country (2024-2024)
5.2 North America Meningococcal Disease Vaccine Forecasted Market Size by Country
5.2.1 North America Meningococcal Disease Vaccine Sales in Volume by Country (2024-2034)
5.2.2 North America Meningococcal Disease Vaccine Sales in Value by Country (2024-2034)
6 Europe Meningococcal Disease Vaccine by Country
6.1 Europe Meningococcal Disease Vaccine Historic Market Size by Country
6.1.1 Europe Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe Meningococcal Disease Vaccine Sales in Volume by Country (2024-2024)
6.1.3 Europe Meningococcal Disease Vaccine Sales in Value by Country (2024-2024)
6.2 Europe Meningococcal Disease Vaccine Forecasted Market Size by Country
6.2.1 Europe Meningococcal Disease Vaccine Sales in Volume by Country (2024-2034)
6.2.2 Europe Meningococcal Disease Vaccine Sales in Value by Country (2024-2034)
7 Asia-Pacific Meningococcal Disease Vaccine by Region
7.1 Asia-Pacific Meningococcal Disease Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific Meningococcal Disease Vaccine Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific Meningococcal Disease Vaccine Sales in Value by Region (2024-2024)
7.2 Asia-Pacific Meningococcal Disease Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Meningococcal Disease Vaccine Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Meningococcal Disease Vaccine Sales in Value by Region (2024-2034)
8 Latin America Meningococcal Disease Vaccine by Country
8.1 Latin America Meningococcal Disease Vaccine Historic Market Size by Country
8.1.1 Latin America Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America Meningococcal Disease Vaccine Sales in Volume by Country (2024-2024)
8.1.3 Latin America Meningococcal Disease Vaccine Sales in Value by Country (2024-2024)
8.2 Latin America Meningococcal Disease Vaccine Forecasted Market Size by Country
8.2.1 Latin America Meningococcal Disease Vaccine Sales in Volume by Country (2024-2034)
8.2.2 Latin America Meningococcal Disease Vaccine Sales in Value by Country (2024-2034)
9 Middle East and Africa Meningococcal Disease Vaccine by Country
9.1 Middle East and Africa Meningococcal Disease Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Meningococcal Disease Vaccine Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa Meningococcal Disease Vaccine Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa Meningococcal Disease Vaccine Sales in Value by Country (2024-2024)
9.2 Middle East and Africa Meningococcal Disease Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Meningococcal Disease Vaccine Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Meningococcal Disease Vaccine Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.1.4 AstraZeneca Meningococcal Disease Vaccine Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information
10.2.2 Johnson & Johnson Introduction and Business Overview
10.2.3 Johnson & Johnson Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Johnson & Johnson Meningococcal Disease Vaccine Products Offered
10.2.5 Johnson & Johnson Recent Development
10.3 Mylan N.V
10.3.1 Mylan N.V Company Information
10.3.2 Mylan N.V Introduction and Business Overview
10.3.3 Mylan N.V Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.3.4 Mylan N.V Meningococcal Disease Vaccine Products Offered
10.3.5 Mylan N.V Recent Development
10.4 Teva Pharmaceutical Industries Ltd
10.4.1 Teva Pharmaceutical Industries Ltd Company Information
10.4.2 Teva Pharmaceutical Industries Ltd Introduction and Business Overview
10.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Products Offered
10.4.5 Teva Pharmaceutical Industries Ltd Recent Development
10.5 Pfizer Inc
10.5.1 Pfizer Inc Company Information
10.5.2 Pfizer Inc Introduction and Business Overview
10.5.3 Pfizer Inc Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Pfizer Inc Meningococcal Disease Vaccine Products Offered
10.5.5 Pfizer Inc Recent Development
10.6 GlaxoSmithKline plc
10.6.1 GlaxoSmithKline plc Company Information
10.6.2 GlaxoSmithKline plc Introduction and Business Overview
10.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.6.4 GlaxoSmithKline plc Meningococcal Disease Vaccine Products Offered
10.6.5 GlaxoSmithKline plc Recent Development
10.7 Novartis AG
10.7.1 Novartis AG Company Information
10.7.2 Novartis AG Introduction and Business Overview
10.7.3 Novartis AG Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Novartis AG Meningococcal Disease Vaccine Products Offered
10.7.5 Novartis AG Recent Development
10.8 Sanofi
10.8.1 Sanofi Company Information
10.8.2 Sanofi Introduction and Business Overview
10.8.3 Sanofi Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.8.4 Sanofi Meningococcal Disease Vaccine Products Offered
10.8.5 Sanofi Recent Development
10.9 Merck & Co., Inc.
10.9.1 Merck & Co., Inc. Company Information
10.9.2 Merck & Co., Inc. Introduction and Business Overview
10.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.9.4 Merck & Co., Inc. Meningococcal Disease Vaccine Products Offered
10.9.5 Merck & Co., Inc. Recent Development
10.10 F. Hoffmann-La Roche Ltd
10.10.1 F. Hoffmann-La Roche Ltd Company Information
10.10.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
10.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.10.4 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Products Offered
10.10.5 F. Hoffmann-La Roche Ltd Recent Development
10.11 Baxter
10.11.1 Baxter Company Information
10.11.2 Baxter Introduction and Business Overview
10.11.3 Baxter Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.11.4 Baxter Meningococcal Disease Vaccine Products Offered
10.11.5 Baxter Recent Development
10.12 BIO-MED
10.12.1 BIO-MED Company Information
10.12.2 BIO-MED Introduction and Business Overview
10.12.3 BIO-MED Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.12.4 BIO-MED Meningococcal Disease Vaccine Products Offered
10.12.5 BIO-MED Recent Development
10.13 Bio-Manguinhos
10.13.1 Bio-Manguinhos Company Information
10.13.2 Bio-Manguinhos Introduction and Business Overview
10.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.13.4 Bio-Manguinhos Meningococcal Disease Vaccine Products Offered
10.13.5 Bio-Manguinhos Recent Development
10.14 Walvax Biotechnology Co., Ltd
10.14.1 Walvax Biotechnology Co., Ltd Company Information
10.14.2 Walvax Biotechnology Co., Ltd Introduction and Business Overview
10.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales, Revenue and Gross Margin (2024-2024)
10.14.4 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Products Offered
10.14.5 Walvax Biotechnology Co., Ltd Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Meningococcal Disease Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Meningococcal Disease Vaccine Industrial Chain Analysis
11.4 Meningococcal Disease Vaccine Market Dynamics
11.4.1 Meningococcal Disease Vaccine Industry Trends
11.4.2 Meningococcal Disease Vaccine Market Drivers
11.4.3 Meningococcal Disease Vaccine Market Challenges
11.4.4 Meningococcal Disease Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Meningococcal Disease Vaccine Distributors
12.3 Meningococcal Disease Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Polysaccharide
Table 2. Major Company of Conjugate
Table 3. Major Company of Combination
Table 4. Global Meningococcal Disease Vaccine Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 5. Global Meningococcal Disease Vaccine Sales by Type (2024-2024) & (K Units)
Table 6. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2024-2024)
Table 7. Global Meningococcal Disease Vaccine Sales by Type (2024-2024) & (US& Million)
Table 8. Global Meningococcal Disease Vaccine Market Share in Value by Type (2024-2024)
Table 9. Global Meningococcal Disease Vaccine Price by Type (2024-2024) & (US$/Unit)
Table 10. Global Meningococcal Disease Vaccine Sales by Type (2024-2034) & (K Units)
Table 11. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Meningococcal Disease Vaccine Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Meningococcal Disease Vaccine Sales Market Share in Value by Type (2024-2034)
Table 14. Global Meningococcal Disease Vaccine Price by Type (2024-2034) & (US$/Unit)
Table 15. North America Meningococcal Disease Vaccine Sales by Type (2024-2024) & (K Units)
Table 16. North America Meningococcal Disease Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 17. Europe Meningococcal Disease Vaccine Sales (K Units) by Type (2024-2024)
Table 18. Europe Meningococcal Disease Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 19. Asia-Pacific Meningococcal Disease Vaccine Sales (K Units) by Type (2024-2024)
Table 20. Asia-Pacific Meningococcal Disease Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 21. Latin America Meningococcal Disease Vaccine Sales (K Units) by Type (2024-2024)
Table 22. Latin America Meningococcal Disease Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 23. Middle East and Africa Meningococcal Disease Vaccine Sales (K Units) by Type (2024-2024)
Table 24. Middle East and Africa Meningococcal Disease Vaccine Sales by Type (2024-2024) & (US$ Million)
Table 25. Global Meningococcal Disease Vaccine Sales by Company (2024-2024) & (K Units)
Table 26. Global Meningococcal Disease Vaccine Sales Share by Company (2024-2024)
Table 27. Global Meningococcal Disease Vaccine Revenue by Company (2024-2024) & (US$ Million)
Table 28. Global Meningococcal Disease Vaccine Revenue Share by Company (2024-2024)
Table 29. Global Market Meningococcal Disease Vaccine Price by Company (2024-2024) & (US$/Unit)
Table 30. Global Meningococcal Disease Vaccine Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Meningococcal Disease Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Meningococcal Disease Vaccine as of 2022)
Table 33. Date of Key Manufacturers Enter into Meningococcal Disease Vaccine Market
Table 34. Key Manufacturers Meningococcal Disease Vaccine Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Meningococcal Disease Vaccine Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 37. Global Meningococcal Disease Vaccine Sales by Region (2024-2024) & (K Units)
Table 38. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Region (2024-2024)
Table 39. Global Meningococcal Disease Vaccine Sales by Region (2024-2024) & (US$ Million)
Table 40. Global Meningococcal Disease Vaccine Sales Market Share in Value by Region (2024-2024)
Table 41. Global Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 42. Global Meningococcal Disease Vaccine Sales by Region (2024-2034) & (K Units)
Table 43. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Meningococcal Disease Vaccine Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Meningococcal Disease Vaccine Sales Market Share in Value by Region (2024-2034)
Table 46. Global Meningococcal Disease Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2034)
Table 47. Global Meningococcal Disease Vaccine Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 48. Global Meningococcal Disease Vaccine Sales by Application (2024-2024) & (K Units)
Table 49. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2024-2024)
Table 50. Global Meningococcal Disease Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 51. Global Meningococcal Disease Vaccine Sales Market Share in Value by Application (2024-2024)
Table 52. Global Meningococcal Disease Vaccine Price by Application (2024-2024) & (US$/Unit)
Table 53. Global Meningococcal Disease Vaccine Sales by Application (2024-2034) & (K Units)
Table 54. Global Meningococcal Disease Vaccine Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Meningococcal Disease Vaccine Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Meningococcal Disease Vaccine Sales Market Share in Value by Application (2024-2034)
Table 57. Global Meningococcal Disease Vaccine Price by Application (2024-2034) & (US$/Unit)
Table 58. North America Meningococcal Disease Vaccine Sales by Application (2024-2024) (K Units)
Table 59. North America Meningococcal Disease Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 60. Europe Meningococcal Disease Vaccine Sales by Application (2024-2024) (K Units)
Table 61. Europe Meningococcal Disease Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 62. Asia-Pacific Meningococcal Disease Vaccine Sales by Application (2024-2024) (K Units)
Table 63. Asia-Pacific Meningococcal Disease Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 64. Latin America Meningococcal Disease Vaccine Sales by Application (2024-2024) (K Units)
Table 65. Latin America Meningococcal Disease Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 66. Middle East and Africa Meningococcal Disease Vaccine Sales by Application (2024-2024) (K Units)
Table 67. Middle East and Africa Meningococcal Disease Vaccine Sales by Application (2024-2024) & (US$ Million)
Table 68. North America Meningococcal Disease Vaccine Sales by Country (2024-2024) & (K Units)
Table 69. North America Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 70. North America Meningococcal Disease Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 71. North America Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2024)
Table 72. North America Meningococcal Disease Vaccine Sales by Country (2024-2034) & (K Units)
Table 73. North America Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Meningococcal Disease Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Meningococcal Disease Vaccine Sales by Country (2024-2024) & (K Units)
Table 77. Europe Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 78. Europe Meningococcal Disease Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 79. Europe Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2024)
Table 80. Europe Meningococcal Disease Vaccine Sales by Country (2024-2034) & (K Units)
Table 81. Europe Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Meningococcal Disease Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Meningococcal Disease Vaccine Sales by Region (2024-2024) & (K Units)
Table 85. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Volume by Region (2024-2024)
Table 86. Asia-Pacific Meningococcal Disease Vaccine Sales by Region (2024-2024) & (US$ Million)
Table 87. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Value by Region (2024-2024)
Table 88. Asia-Pacific Meningococcal Disease Vaccine Sales by Region (2024-2034) & (K Units)
Table 89. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Meningococcal Disease Vaccine Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Meningococcal Disease Vaccine Sales by Country (2024-2024) & (K Units)
Table 93. Latin America Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 94. Latin America Meningococcal Disease Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 95. Latin America Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2024)
Table 96. Latin America Meningococcal Disease Vaccine Sales by Country (2024-2034) & (K Units)
Table 97. Latin America Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Meningococcal Disease Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Meningococcal Disease Vaccine Sales by Country (2024-2024) & (K Units)
Table 101. Middle East and Africa Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2024)
Table 102. Middle East and Africa Meningococcal Disease Vaccine Sales by Country (2024-2024) & (US$ Million)
Table 103. Middle East and Africa Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2024)
Table 104. Middle East and Africa Meningococcal Disease Vaccine Sales by Country (2024-2034) & (K Units)
Table 105. Middle East and Africa Meningococcal Disease Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Meningococcal Disease Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Meningococcal Disease Vaccine Sales Market Share in Value by Country (2024-2034)
Table 108. AstraZeneca Company Information
Table 109. AstraZeneca Introduction and Business Overview
Table 110. AstraZeneca Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 111. AstraZeneca Meningococcal Disease Vaccine Product
Table 112. AstraZeneca Recent Development
Table 113. Johnson & Johnson Company Information
Table 114. Johnson & Johnson Introduction and Business Overview
Table 115. Johnson & Johnson Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 116. Johnson & Johnson Meningococcal Disease Vaccine Product
Table 117. Johnson & Johnson Recent Development
Table 118. Mylan N.V Company Information
Table 119. Mylan N.V Introduction and Business Overview
Table 120. Mylan N.V Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 121. Mylan N.V Meningococcal Disease Vaccine Product
Table 122. Mylan N.V Recent Development
Table 123. Teva Pharmaceutical Industries Ltd Company Information
Table 124. Teva Pharmaceutical Industries Ltd Introduction and Business Overview
Table 125. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 126. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product
Table 127. Teva Pharmaceutical Industries Ltd Recent Development
Table 128. Pfizer Inc Company Information
Table 129. Pfizer Inc Introduction and Business Overview
Table 130. Pfizer Inc Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 131. Pfizer Inc Meningococcal Disease Vaccine Product
Table 132. Pfizer Inc Recent Development
Table 133. GlaxoSmithKline plc Company Information
Table 134. GlaxoSmithKline plc Introduction and Business Overview
Table 135. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 136. GlaxoSmithKline plc Meningococcal Disease Vaccine Product
Table 137. GlaxoSmithKline plc Recent Development
Table 138. Novartis AG Company Information
Table 139. Novartis AG Introduction and Business Overview
Table 140. Novartis AG Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 141. Novartis AG Meningococcal Disease Vaccine Product
Table 142. Novartis AG Recent Development
Table 143. Sanofi Company Information
Table 144. Sanofi Introduction and Business Overview
Table 145. Sanofi Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 146. Sanofi Meningococcal Disease Vaccine Product
Table 147. Sanofi Recent Development
Table 148. Merck & Co., Inc. Company Information
Table 149. Merck & Co., Inc. Introduction and Business Overview
Table 150. Merck & Co., Inc. Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 151. Merck & Co., Inc. Meningococcal Disease Vaccine Product
Table 152. Merck & Co., Inc. Recent Development
Table 153. F. Hoffmann-La Roche Ltd Company Information
Table 154. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 155. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 156. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product
Table 157. F. Hoffmann-La Roche Ltd Recent Development
Table 158. Baxter Company Information
Table 159. Baxter Introduction and Business Overview
Table 160. Baxter Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 161. Baxter Meningococcal Disease Vaccine Product
Table 162. Baxter Recent Development
Table 163. BIO-MED Company Information
Table 164. BIO-MED Introduction and Business Overview
Table 165. BIO-MED Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 166. BIO-MED Meningococcal Disease Vaccine Product
Table 167. BIO-MED Recent Development
Table 168. Bio-Manguinhos Company Information
Table 169. Bio-Manguinhos Introduction and Business Overview
Table 170. Bio-Manguinhos Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 171. Bio-Manguinhos Meningococcal Disease Vaccine Product
Table 172. Bio-Manguinhos Recent Development
Table 173. Walvax Biotechnology Co., Ltd Company Information
Table 174. Walvax Biotechnology Co., Ltd Introduction and Business Overview
Table 175. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 176. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product
Table 177. Walvax Biotechnology Co., Ltd Recent Development
Table 178. Key Raw Materials Lists
Table 179. Raw Materials Key Suppliers Lists
Table 180. Meningococcal Disease Vaccine Market Trends
Table 181. Meningococcal Disease Vaccine Market Drivers
Table 182. Meningococcal Disease Vaccine Market Challenges
Table 183. Meningococcal Disease Vaccine Market Restraints
Table 184. Meningococcal Disease Vaccine Distributors List
Table 185. Meningococcal Disease Vaccine Downstream Customers
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Meningococcal Disease Vaccine Product Picture
Figure 2. Global Meningococcal Disease Vaccine Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Meningococcal Disease Vaccine Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global Meningococcal Disease Vaccine Sales Status and Outlook (2024-2034) & (K Units)
Figure 5. Product Picture of Polysaccharide
Figure 6. Global Polysaccharide Sales YoY Growth (2024-2034) & (K Units)
Figure 7. Product Picture of Conjugate
Figure 8. Global Conjugate Sales YoY Growth (2024-2034) & (K Units)
Figure 9. Product Picture of Combination
Figure 10. Global Combination Sales YoY Growth (2024-2034) & (K Units)
Figure 11. Global Meningococcal Disease Vaccine Sales by Type (2024-2034) & (US$ Million)
Figure 12. Global Meningococcal Disease Vaccine Sales Market Share by Type in 2022 & 2034
Figure 13. North America Meningococcal Disease Vaccine Sales Market Share in Volume by Type in 2022
Figure 14. North America Meningococcal Disease Vaccine Sales Market Share in Value by Type in 2022
Figure 15. Europe Meningococcal Disease Vaccine Sales Market Share in Volume by Type in 2022
Figure 16. Europe Meningococcal Disease Vaccine Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Value by Type in 2022
Figure 19. Latin America Meningococcal Disease Vaccine Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Meningococcal Disease Vaccine Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Meningococcal Disease Vaccine Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Meningococcal Disease Vaccine Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Meningococcal Disease Vaccine Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Meningococcal Disease Vaccine Revenue in 2022
Figure 25. Meningococcal Disease Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 26. Product Picture of Infant
Figure 27. Global Infant Sales YoY Growth (2024-2034) & (K Units)
Figure 28. Product Picture of Child
Figure 29. Global Child Sales YoY Growth (2024-2034) & (K Units)
Figure 30. Product Picture of Aldult
Figure 31. Global Aldult Sales YoY Growth (2024-2034) & (K Units)
Figure 32. Global Meningococcal Disease Vaccine Sales by Application (2024-2034) & (US$ Million)
Figure 33. Global Meningococcal Disease Vaccine Sales Market Share by Application in 2022 & 2034
Figure 34. North America Meningococcal Disease Vaccine Sales Market Share in Volume by Application in 2022
Figure 35. North America Meningococcal Disease Vaccine Sales Market Share in Value by Application in 2022
Figure 36. Europe Meningococcal Disease Vaccine Sales Market Share in Volume by Application in 2022
Figure 37. Europe Meningococcal Disease Vaccine Sales Market Share in Value by Application in 2022
Figure 38. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Volume by Application in 2022
Figure 39. Asia-Pacific Meningococcal Disease Vaccine Sales Market Share in Value by Application in 2022
Figure 40. Latin America Meningococcal Disease Vaccine Sales Market Share in Volume by Application in 2022
Figure 41. Latin America Meningococcal Disease Vaccine Sales Market Share in Value by Application in 2022
Figure 42. Middle East and Africa Meningococcal Disease Vaccine Sales Market Share in Value by Application in 2022
Figure 43. Key Raw Materials Price
Figure 44. Meningococcal Disease Vaccine Manufacturing Cost Structure
Figure 45. Meningococcal Disease Vaccine Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries